# Investigating Metabolically Altered Pathways in Small Cell Lung Cancer: From RNA Sequencing Analysis to Seahorse-Based Functional Validation

## TL;DR

This study explores how inhibiting DDX5 disrupts mitochondrial function in small cell lung cancer, offering new insights into a potential targeted therapy.

## Contribution

The study reveals a novel role of DDX5 in mitochondrial regulation and validates the mechanism of Supinoxin's anti-tumor activity.

## Key findings

- Supinoxin treatment and DDX5 knockdown downregulated genes involved in cellular respiration in SCLC cells.
- Seahorse XF tests showed mitochondrial dysfunction in Supinoxin-treated cells, confirming disrupted energy metabolism.
- DDX5 inhibition offers a potential therapeutic strategy by targeting mitochondrial regulation in SCLC.

## Abstract

Small cell lung cancer (SCLC) is an aggressive malignancy characterized by rapid progression, early metastasis, and high relapse rates due to acquired chemoresistance. The human DEAD-box RNA helicase DDX5 is overexpressed in SCLC and has recently gained attention as a viable therapeutic target. Supinoxin (RX-5902), a selective small-molecule inhibitor of DDX5, exhibits strong anti-tumor activity. Recent evidence suggests that its cytotoxic effects are mediated through the disruption of mitochondrial respiration. In this study, transcriptomic profiling via RNA sequencing (RNA-seq) revealed significant downregulation of genes involved in cellular respiration following Supinoxin treatment and DDX5 knockdown in chemoresistant H69AR cells. To functionally validate these findings, we employed the Seahorse XF Cell Mito Stress Test, which measures key parameters of mitochondrial bioenergetics through oxygen consumption rate (OCR) analysis. Supinoxin-treated cells exhibited marked mitochondrial dysfunction, supporting the hypothesis that DDX5 inhibition disrupts cellular energy metabolism. These findings illuminate a previously underappreciated role of DDX5 in mitochondrial regulation and offer mechanistic insights into Supinoxin’s cytotoxic effects, underscoring its potential as a targeted therapy in SCLC.